KPTI News and Press, Karyopharm Therapeutics Inc. From 05/12/20

NEWTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Health...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Image source: The Motley Fool. Karyopharm Therapeutics Inc   (NASDAQ: KPTI) Q1 2020 Earnings Call May 5, 2020 , 8:30 a.m. ET Operator Continue reading

Karyopharm Therapeutics Inc. (KPTI) Q1 2020 Earnings Conference Call May 5, 2020, 08:30 AM ET Company Participants Ian Karp - VP, Investor and Public Relations Michael Kauffman - CEO John Demaree - Chief Commercial Officer Mike Mason - CFO Perry Monaco - SVP, Sales Chris Pr...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2020 Q1 earnings Read more ...

Hertz Global Holdings (NYSE: HTZ )  -16%  after it enters into forbearances and limited waivers . More news on: Hertz Global Holdings, Inc., Centennial Resource Development, Inc., Compass Diversified Holdings LLC, Stocks on the move, , Read more ...

Karyopharm Therapeutics ( KPTI ) Q1 results : More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Karyopharm Therapeutics (NASDAQ: KPTI ): Q1 GAAP EPS of -$0.78 misses by $0.07 . More news on: Karyopharm Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Pivotal Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival; Oral Presentation at ASCO 2020 Virtual Scientific Program and sNDA To Be Submitted by End of May 2020 -- -- First Quarter 2020 XPOVIO Net Product Sales of $16.1 Million a...

Karyopharm Therapeutics ( KPTI -5.3% ) is collaborating with contract research organization (CRO) PROMETRIKA on an international, randomized, 230-subject study evaluating low-dose Xpovio (selinexor) in severely ill hospitalized COVID-19 patients. More news on: Karyopharm Therapeutics I...